Pancreatic islet xenograft tolerance after short-term costimulation blockade is associated with increased CD4+ T cell apoptosis but not immune deviation

Transplantation

Volumn 69, Issue 6, 2000, Pages 1176-1185

  Lehnert, Anne M ^a   Yi, Shounan ^a   Burgess, Jane S ^a   O'Connell, Philip J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CD4 ANTIGEN;

ALLOGRAFT; ANIMAL CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CELL SPECIFICITY; CELL STIMULATION; CELL SURVIVAL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; RECEPTOR BLOCKING; T LYMPHOCYTE ACTIVATION; XENOGRAFT;

EID: 0034719664     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003270-00024     Document Type: Article

References (48)

1. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T-cell activation pathway. Science 1989; 244: 339.
2. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA4 and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065.
3. Razi-wolf Z, Freeman GJ, Galvin R, Benacerraf B, Nadler L, Reiser H. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci USA 1992; 89: 4210.
4. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165.
5. Green JM, Noel PJ, Sperling AI, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994; 1: 501.
6. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its Iigand gp39. Annu Rev Immunol 1996; 14: 591.
7. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881.
8. Armitage RJ, Tough TW, Macduff BM, et al. CD40 ligand is a T-cell growth factor. Eur J Immunol 1993; 23: 2326.
9. Stout RD, Suttles J, Xu J, Grewal S, Flavell RA. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 1996; 156: 8.
10. Borrow P, Tishon A, Lee S, et al. CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CDS+ CTL response. J Exp Med 1996; 183: 2129.
11. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA4 is a second receptor for the B-cell activation antigen B7. J Exp Med 1991; 174: 561.
12. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
13. Lenschow DJ, Zeng Y, Thistlewaite R, et al. Long term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig. Science 1992; 257: 789.
14. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994; 57: 1701.
15. Sayegh MH, Aklin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869.
16. Tran HM, Nickerson PW, Restifo AC, et al. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol 1997; 159: 2232.
17. Steurer W, Nickerson PW, Steele AW, Steiger J, Zeng XX, Strom TB. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995; 155: 1165.
18. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
19. Tran HM, Nickerson PW, Patel A, Strom TB, Allen RDM, O'Connell PJ. Short -term suppression of the xeno-immune response with mCTLA-Fc treatment. Xenotranplantation 1997; 4: 222.
20. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
21. Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal anti-body treatment. J Immunol 1999; 162: 4983.
22. Li Y, Zheng XX, Li CX, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 1387.
23. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177: 925.
24. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996; 93: 13967.
25. Waldman H, Cobbold S. How do monoclonal antibodies induce tolerance? Annu Rev Immunol 1998; 16: 619.
26. Scully R, Qin S, Cobbold SP, Waldmann H. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T-cells. Eur J Immunol 1994; 24: 2383.
27. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992; 89: 6550.
28. Medbury HJ, Hibbins M, Lehnert AM, et al. The cytokine and histological response in islet xenograft rejection is dependent upon species combination. Transplantation 1997; A64: 1307.
29. Tran HM, Patel A, Allen RDM, O'Connell PJ. Intrathymic inoculation of donor antigen: and ineffective strategy for prolonging xenograft survival. Xenotransplantation 1999; 6: 1.
30. Goss JA, Nakafusa Y, Finke EH, Flye MW, Lacy PE. Induction of tolerance of islet xenografts in a concordant rat-to-mouse model. Diabetes 1994; 43: 16.
31. Elwood ET, Larsen CP, Cho HR, et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 1998; 65: 1422.
32. Gordon EJ, Markees TG, Phillips NE, et al. Prolonged survival of rat islet and skin xenografts in mice treated with donor spleno-cytes and anti-CD154 monoclonal antibody. Diabetes 1998; 47 (8): 1199.
33. Pankewycz OJ, Mackie J, Hasarjian R, Murphy JR, Strom TB, Kelley VE. Interleukin-2-diptheria toxin fusion protein prolongs murine islet cell engraftment. Transplantation 1989; 47: 318.
34. Hao L, Calcinro F, Gill RG, Eugui E, Allison AC, Lafferty KJ. Facilitation of specific tolerance induction in adult mice by RS-61443. Transplantation 1992; 53: 590.
35. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: the differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
36. Onodera K, Hancock WW, Graser E, et al. Type 2 helper T-cell type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients. J Immunol 1997; 158: 1572.
37. Li XC, Zand MS, Li Y, Zheng XX, Strom TB. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol 1998; 161: 2241.
38. Morris CF, Simeonovic CJ, Fung M-C, Wilson JD, Hapel AJ. Intragraft expression of cytokine transcripts during pig proislet xenograft rejection and tolerance in mice. J Immunol 1995; 154: 2470.
39. Cory S. Regulation of lymphocyte survival by the Bcl-2 gene family. Annu Rev Immunol 1995; 13: 513.
40. Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediated activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441.
41. Ju ST, Panka D, Cui H, et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444.
42. Van Parijs L, Biuckians A, Ibraghimov A, Alt FW, Willerford D, Abbas A. Functional responses and apoptosis in CD25 (IL-2Ra)-deficient lymphocytes expressing a transgenic antigen receptor. J Immunol 1997; 158: 3738.
43. Kneitz B, Herrmann T, Yonehara S, Schimpl A. Normal clonal expansion but impaired Fas-mediated cell death and anergy in IL-2 deficient mice. Eur J Immunol 1995; 25: 2572.
44. Li XC, Roy-Chaudhury P, Hancock WW, et al. IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T-cell growth factors in Allograft rejection. J Immunol 1998; 161: 890.
45. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998; 161: 1659.
46. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Natl Med 1999; 5(11): 1298.
47. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Med 1999; 5: 686.
48. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Natl Med 1999; 5 (11): 1303.